A patient has been taking buspirone (Buspar) 5 mg twice daily for three months without improvement and now has persistent anxiety with obsessive checking, constant leg restlessness (possible akathisia), low mood and crying. What is the appropriate next step in management?

Discontinue buspirone and initiate an SSRI for likely OCD with comorbid depression

This patient requires a medication change—buspirone is ineffective for obsessive-compulsive symptoms and may be contributing to akathisia (leg shaking). The clinical presentation of obsessive checking behaviors, persistent worry, motor restlessness, low mood, and crying after 3 months of inadequate buspirone treatment indicates the need for first-line pharmacotherapy with an SSRI.

Why Buspirone Has Failed

Buspirone at 5 mg twice daily (10 mg/day total—not the stated "75 mg") is:

• Substantially underdosed: Maximum recommended dose is 60 mg/day (20 mg three times daily), with therapeutic range typically 30-60 mg/day 1
• Wrong medication class: Buspirone is "useful only in patients with mild to moderate agitation" and requires 2-4 weeks to become effective 1. It has no established efficacy for OCD 2
• Potentially causing akathisia: The constant leg shaking may represent buspirone-induced akathisia or restlessness, which is a recognized adverse effect 3, 4, 5

The Correct Diagnosis and Treatment

The obsessive checking (door locks), persistent worry, motor restlessness, anhedonia ("don't want to do anything"), and crying suggest OCD with comorbid depressive symptoms.

First-Line Treatment: SSRIs

Initiate an SSRI immediately as these are the established first-line pharmacotherapy for OCD 2:

• Sertraline: Start 25-50 mg/day, target 200 mg/day (well-tolerated, fewer drug interactions) 1
• Fluoxetine: Start 10 mg every other morning, target 40-80 mg/day (long half-life, activating) 1
• Paroxetine: Start 10 mg/day, target 40-60 mg/day (more sedating, higher discontinuation risk) 6, 1
• Fluvoxamine: Start 50 mg twice daily, target 300 mg/day (more drug interactions via CYP450) 6, 1

Critical dosing principle: OCD typically requires higher SSRI doses and longer trials (10-12 weeks) than generalized anxiety or depression 7, 2. Don't undertreate.

Titration Strategy

• Start at subtherapeutic "test dose" to assess tolerability, as SSRIs can initially increase anxiety 6
• Increase dose every 1-2 weeks for shorter half-life SSRIs (sertraline, paroxetine) or 3-4 weeks for fluoxetine 6
• Continue titration until therapeutic response or maximum tolerated dose
• Allow minimum 8-12 weeks at therapeutic dose before declaring treatment failure 7

Addressing the Motor Restlessness

The leg shaking requires immediate assessment:

1. If akathisia from buspirone: Will resolve with discontinuation 4, 5
2. If anxiety-related restlessness: Should improve with SSRI treatment
3. If SSRI-induced akathisia develops: Consider dose reduction, beta-blockers (propranolol), or benzodiazepines short-term 8

Do not use buspirone to treat akathisia—it showed limited efficacy and even worsened symptoms in some patients 4.

Critical Warnings When Prescribing SSRIs

• Monitor for serotonin syndrome, especially if combining with other serotonergic agents 3
• Assess for suicidal ideation regularly, particularly in first 4-8 weeks and after dose changes 6
• Avoid abrupt discontinuation of shorter-acting SSRIs (paroxetine, fluvoxamine, sertraline) due to discontinuation syndrome 6
• Screen for bipolar disorder before initiating—SSRIs can precipitate mania

Augmentation if SSRI Monotherapy Fails

After adequate SSRI trial (12 weeks at maximum tolerated dose), consider:

1. Add cognitive-behavioral therapy (CBT) with exposure and response prevention—this is the most evidence-based augmentation 7, 2
2. Augment with low-dose atypical antipsychotic (risperidone 0.25-2 mg/day, aripiprazole 5-15 mg/day) 1, 7
3. Switch to clomipramine (tricyclic with strong serotonergic properties, 150-250 mg/day)—equally effective to SSRIs but more side effects 2

What NOT to Do

• Do not increase buspirone dose—it lacks efficacy for OCD regardless of dose 2
• Do not use benzodiazepines long-term—risk of dependence, cognitive impairment, and paradoxical agitation 1, 9
• Do not combine buspirone with MAOIs—risk of hypertensive crisis 3
• Do not expect rapid response—OCD treatment requires patience and persistence

Practical Implementation

1. Discontinue buspirone (can stop abruptly at this low dose)
2. Start SSRI (sertraline 25-50 mg/day is reasonable first choice)
3. Refer for CBT with exposure and response prevention concurrently
4. Follow-up in 1-2 weeks to assess tolerability and side effects
5. Continue weekly contact during titration phase 6
6. Reassess at 8-12 weeks at therapeutic dose before declaring failure

The combination of SSRI plus CBT provides superior outcomes compared to either alone for anxiety disorders 6, and this principle likely extends to OCD with depressive features.